



MARYLAND DEPARTMENT OF HEALTH
Medicaid Pharmacy Program

ADVISORY

No. 192

January 18, 2019

Brand Reyataz® Removal from DAW 6 Program

The Maryland Medicaid Pharmacy Program (MMPP) wants to alert you that effective Friday, February 15, 2019 brand Reyataz® capsules will no longer be preferred over its generic equivalent (atazanavir sulfate). Claims for atazanavir sulfate capsules will be handled in the same manner as claims for other multisource medications. Claims for brand Reyataz® capsules will adjudicate only if there is a prior authorization based on an approved Maryland Department of Health (MDH) Medwatch form which can be found at the following link:

<https://mmcp.health.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf>

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Maryland Medicaid Pharmacy Program (MMPP)** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.